Skip to Content

'
Steven H. Lin, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty, Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My laboratory has several lines of research.  The first is to identify novel agents to combine with radiation to enhance treatment effects through the application of high throughput screening methods.  Second, I am interested in identifying novel gene targets that could enhance the systemic immune response in combination with radiation therapy.  Third, I am seeking ways through imaging or blood based markers to assess response to treatment for lung and esophageal cancer patients. 

Clinical Interests

My clinical interests lie in improving the clinical outcomes of lung and esophageal cancer patients receiving radiation therapy.  I have a special interest in the application of advanced radiation technologies such as Intensity Modulated Radiation Therapy (IMRT) and proton beam therapy as a way to minimize toxicity for esophageal cancer patients.  I also have interest in using various imaging and blood based biomarkers to predict for response to treatment.

Education & Training

Degree-Granting Education

2004 University of California, Irvine, CA, MD, Medicine
2004 University of California, Irvine, CA, PHD, Pharmacology
1995 University of California, Riverside, CA, MS, Biochemistry
1994 University of California, Riverside, CA, BS, Biology
1992 California Polytechnic University, Pomona, CA, None, Architecture (transferred)

Postgraduate Training

7/2005-8/2009 Clinical Residency, Radiation Oncology, The John Hopkins Hospital, Baltimore, MD, Ted L. DeWeese
7/2004-6/2005 Clinical Internship, Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA
6/2001-7/2002 Post-Ph.D., Neuropharmacology, Neogene Technologies, Irvine, CA, Olivier Civelli

Board Certifications

5/2010 American Board of Radiology

Experience/Service

Institutional Committee Activities

Committee Member and Grants Reviewer, Institutional Research Grant Committee-Basic Study Section Committee, 4/2013-present
Associate Member, Institutional Review Board 5, 8/2011-present

Honors and Awards

2014-2016 R. Lee Clark Fellow, Clinical Innovator Panel, MD Anderson Cancer Center
2012-2014 Comparative Effectiveness Research on Cancer in Texas Fellow, CERCIT
2010-2013 ASTRO Junior Faculty Fellow, American Society for Radiation Oncology (ASTRO)
2008-2009 RSNA Research Resident Grant
2008 ABS/Nucletron HDR Brachytherapy Fellowship
2004 Alpha Omega Alpha, University of California, Irvine School of Medicine
2001 Henry Wood Elliott Award in Pharmacology
1998 American Heart Association Medical Student Fellowship
1997 UC Regents Research Fellowship
1996-1997 Dean's Award, University of California, Irvine School of Medicine
1996 Donald E. Pinder, M.D. Memorial Award
1996 Dr. Grace Bell Award
1995-2004 Medical Scientist Training Program Fellowship and Stipend
1994 Phi Beta Kappa, University of California
1994 Summa Cum Laude, University of California

Selected Publications

Peer-Reviewed Original Research Articles

1. Lin SH, Wang J, Allen PK, Correa AM, Maru D, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. Nomogram for Pathologic Complete Response to Neoadjuvant Chemoradiation also Predicts Survival Outcomes after Definitive Chemoradiation for Esophageal Cancer. J Gastro Oncol. In Press.
2. Ly NB, Allen PK, Lin SH. Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature. J Radiat Oncol. In Press.
3. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z,Lin SH. Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. J Thorac Oncol 9(9):1398-405, 9/2014.
4. Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 9(7):965-73, 7/2014.
5. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. Ann Thorac Surg. e-Pub 7/2014.
6. Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL,Lin SH. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. e-Pub 4/2014.
7. Juloori A, Tucker SL, Komaki R, Liao X, Correa AM, Swisher SG, Hofstetter WL,Lin SH. Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy. J Thorac Oncol 9(4):534-40, 2014.
8. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and Outcomes in Patients Treated with Chemoradiotherapy for Esophageal Carcinoma. Dis Esophagus 27(2):168-75, 2014.
9. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X,Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124:2696-2708, 2014.
10. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Ajani JA, Cox JD, Komaki R, Liao Z,Lin SH. Predictors for Postoperative Complications after Trimodality Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 86(5):885-91, 8/2013.
11. Cheedella NK1, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-6, 5/2013.
12. Wu CC, Kannan K,Lin SH,Yen L, Milosavlijevic A. Identification of cancer fusion drivers using network fusion centrality. Bioinformatics. e-Pub 5/2013.
13. Lin SH, George T, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman N, Vikram B, Yoo S, Chung C. Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. J Natl Cancer Inst. e-Pub 3/2013.
14. Skinner, H. D., McCurdy, M. R., Echeverria, A. E., Lin, S. H, Welsh J, O'Reilly, M. S., Hofstetter, W. L., Ajani J.A., Komaki, R., Cox, J. D., Sandulache, V. C., Myers, J. N., Guerrero, T. M. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-9, 2013.
15. Armini A, Feiran L, Corea AM, Baldessare R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA,Lin SH. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol 20:1934-40, 2013.
16. Lopez Guerra JL1, Gomez DR,Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24:67-74, 2013.
17. Zhang X,Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 8(12):1484-91, 2013.
18. Lin SH, Myles B, Wang L, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score based comparison of long term outcomes with 3D conformal radiotherapy (3DCRT) versus Intensity Modulated Radiation Therapy (IMRT) in treatment of esophageal cancer. Int J Radiat Oncol Biol Phy 84(5):1078-85, 12/2012. PMID: 22867894.
19. Saintigny P, Massarelli E,Lin SH, Ahn YH, Chen Y, Goswani S, Erez B. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Research, 11/2012. e-Pub 11/2012.
20. Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M,Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 Gene Polymorphisms Predict Risk of Mortality for US Patients After Radio(chemo)therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(2):e229-e235, 10/2012. e-Pub 5/2012. PMCID: PMC3426644.
21. Skinner HD, McCurdy MR, Echeverria AE,Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. e-Pub 9/2012. PMID: 22950385.
22. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J,Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5). e-Pub 9/2012. PMID: 22964903.
23. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 9/2012. e-Pub 12/2011. PMID: 22150920.
24. Lopez Guerra JL, Gomez DR,Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol. e-Pub 9/2012. PMID: 23002278.
25. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA,Lin SH. The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy. Ann Thorac Surg 94(3):914-920, 9/2012. e-Pub 7/2012. PMID: 22819472.
26. Amini A, Correa AM, Komaki R, Chang JY, Greer S, Tsao AS, Pisters KM, Roth JA, Swisher SG, Rice DC, Vaporciyan AA,Lin SH. The Role of Consolidative Therapy for Patients with Stage III Non-Small Cell Lung Cancer with Persistent N2 Disease after Induction Chemotherapy. Annals of Thoracic Surgery 94(3):914-20, 9/2012.
27. Yu ZH, Lin SH, Balter P, Zhang L, Dong L. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers. Radiother Oncol 104(1):33-38, 7/2012. e-Pub 6/2012. PMID: 22677039.
28. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J,Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. e-Pub 7/2012. PMID: 22853875.
29. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J,Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. e-Pub 7/2012. PMID: 22831985.
30. Chung H, Court L,Lin SH, Kulkarni D, Balter P. Evaluation of dose variation to normal/critical structures for lung hypofractionated stereotactic body radiation therapy. Practical Rad Onc 2(3), 7/2012.
31. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton Beam Therapy and Concurrent Chemotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 83(3):e345-e351, 7/2012. e-Pub 3/2012. PMID: 22417808.
32. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, Cox JD, Starkschall G. Quantifying the Interfractional Displacement of the Gastroesophageal Junction during Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 83(2):e273-e280, 6/2012. e-Pub 3/2012. PMID: 22440040.
33. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J,Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4822-33, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
34. Hristov B, Reddy S,LinSH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 76(1):176-80, 1/2010. PMID: 19394156.
35. Tan AC, Jimeno A,Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3(5-6):425-38, 12/2009. e-Pub 4/2009. PMID: 19497796.
36. Yi JM, Tsai HC, Glöckner SC,Lin SH, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Res 68(19):8094-8103, 10/2008. PMCID: PMC2744404.
37. Lin SH, Sugar E, Teslow T, McNutt T, Saleh H, Song DY. Comparison of daily couch shifts using MVCT (TomoTherapy) and B-mode Ultrasound (BAT system) during prostate radiotherapy. Technol Cancer Res Treat 7(4):279-286, 8/2008. PMID: 18642966.
38. Lin SH, Kleinberg LR. Carmustine Wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343-359, 3/2008. PMID: 18366283.
39. Lin SH, Latronico D, Teslow T, Bajaj GK. A highly reproducible bolus immobilization technique for the treatment of scalp malignancies. Med Dosim 33(1):30-35, 2008. PMID: 18262120.
40. Lin SH. Prolactin Releasing Peptide. Results Probl Cell Differ 46:57-88, 2008. PMID: 18204826.
41. Nagasaki H, Wang Z, Jackson VR,Lin SH, Nothacker HP, Civelli O. Differential expression of the thyrostimulin subunits, glycoprotein alpha2 and beta5 in the rat pituitary. J Mol Endocrinol 37(1):39-50, 8/2006. PMID: 16901922.
42. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. A study of the rat neuropeptide B/neuropeptide W system using in situ techniques. J Comp Neurol 497(3):367-383, 7/2006. PMID: 16736466.
43. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z,Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43(4):487-497, 8/2004. PMID: 15312648.
44. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann Med 36(3):204-214, 2004. PMID: 15181976.
45. Lin SH, Leslie FM, Civelli O. Neurochemical properties of the PrRP receptor expressing neurons: Evidence for a role as a regulator of stress and nociception. Brain Res 952:15-30, 2002. PMCID: PMC12363400.
46. Civelli O, Nothacker HP, Saito Y, Wang Z,Lin SH, Reinscheid RK. Novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci 24(4):230-237, 4/2001. PMID: 11250008.
47. Lin SH, Arai A, Wang Z, Nothacker HP, Civelli O. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in a-amino3- hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. Mol Pharmacol 60:916-924, 2001. PMCID: PMC11641419.
48. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK,Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58(6):1601-1608, 2000. PMCID: PMC1193801.
49. Saito Y, Nothacker HP, Wang Z,Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating hormone receptor. Nature 400(400):265-269, 7/1999. PMID: 10421368.

Book Chapters

1. Lin SH, Komaki R. Molecular Targeted Treatment for Personalized Radiotherapy in Lung Cancer. In: Lung Cancer, 4th Edition. Ed(s) JA Roth, WK Hong, R Komaki. John Wiley & Sons, Inc, 2014.
2. Lin SH, Liao Z. Esophageal Cancer. In: Decision Making in Radiation Oncology, 2nd Edition. Ed(s) Lu JJ, Brady LW. Springer-Verlag: Heidelberg, Germany, 329-358, 2010.
3. Lin SH, Chang JY. Lung Cancer. In: Decision Making in Radiation Oncology, 2nd Edition. Ed(s) Lu JJ, Brady LW. Springer-Verlag: Heidelberg, Germany, 261-307, 2010.

Books (edited and written)

1. Hristov B, Lin SH, Christodouleas JP. Ed(s) Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review, 2nd edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany. In Press.
2. Hristov B, Lin SH, Christodouleas JP. Ed(s) Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. In: Radiation Oncology: A Question-based Review, 1st Edition. Wolters Kluwer, Lippincott, Williams & Wilkins: Germany, 2011.

Grant & Contract Support

Title: Mapping Protin RBE Variability Using Automated Biology and Montre Carlo Techniques, Awarded
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Grosshans
Duration: 8/1/2014 - 7/31/2016
 
Title: University of Texas SPORE in Lung Cancer, Awarded
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: John Minna and Jack Roth
Duration: 2014 - 2019
 
Title: Phase I trial combining trametinib with chemoradiation in Kras mutant lung cancer, Awarded
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 11/1/2013 - 10/31/2015
 
Title: Research and Development of Novel Radiation Sensitizers, Awarded
Funding Source: STCube Pharmaceuticals Inc.
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2016
 
Title: Transcriptomic Correlates of Pathologic Complete Response and Residual Disease after Neoadjuvant Chemoradiation in Esophageal Cancer, Awarded
Funding Source: MD Anderson Cancer Center
Role: Principal Investigator
Duration: 8/1/2013 - 1/31/2015
 
Title: Functional Magnetic Resonance Imaging for Response Assessment to Chemoradiation in Esophageal Cancer, Awarded
Funding Source: Elekta LLC
Role: Principal Investigator
Duration: 7/1/2013 - 1/31/2015
 
Title: High Throughput Synthetic Lethal Drug Screen to Identify Novel Radiation Sensitizers for Kras Mutant Non-Small Cell Lung Cancer, Awarded
Funding Source: MD Anderson Cancer Center
Role: Principal Investigator
Duration: 7/1/2013 - 1/31/2015
 
Title: Improving Our Understanding and Maximizing the Effectiveness of Proton Therapy”, Awarded
Funding Source: Center for Radiation Oncology Research
Role: Co-Principal Investigator
Duration: 7/1/2013 - 6/30/2014
 
Title: Kras mutation targeting to enhance radiation response in non-small cell lung cancer, Awarded
Funding Source: Uniting Against Lung Cancer
Role: Principal Investigator
Duration: 3/1/2013 - 2/28/2015
 
Title: Molecular Predictors of Radiation Resistance in Postoperative Radiation Patients, Awarded
Funding Source: MDACC Lung Cancer Priority Program
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2014
 
Title: Investigating the Prognostic Significance of Circulating Tumor Cells in Epithelial Mesenchymal Transition in Lung Cancer Patients During and After Chemoradiation, Awarded
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2012
 
Title: Predicting Metastasis and Primary Radiation Resistance Using a DNA Methylation Signature for Epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer Patients, Awarded
Funding Source: American Society for Therapeutic Radiology and Oncology (ASTRO)
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2012
 
Title: Methylation Biomarker Profiling for Chemotherapy Response in Non-Small Cell Lung, Awarded
Funding Source: University of Texas SPORE in Lung Cancer
Role: Principal Investigator
Duration: 1/1/2010 - 12/31/2010

Last updated: 9/12/2014